other material
confidence high
sentiment positive
materiality 0.65
Axsome initiates Phase 3 ENGAGE trial of solriamfetol for binge eating disorder
Axsome Therapeutics, Inc.
- Initiated ENGAGE Phase 3 trial of solriamfetol for binge eating disorder.
- Trial is randomized, double-blind, placebo-controlled with ~450 patients.
- Two doses (150 mg and 300 mg) vs placebo for 12 weeks; primary endpoint is change in binge eating episodes.
- First patient screened in March 2024.